Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07850609 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

Name: A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018) — clinical trial record (NCT07850609)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EXPrESSIVE-18

StatusNot Yet Recruiting

PhasePhase 2

SponsorMerck Sharp & Dohme LLC

Started2026-10-29

View on ClinicalTrials.gov ↗

Merck (MSD)

401 trials monitored

See 24 trials at risk

The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.

Trial Details

NCT Number	NCT07850609
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	HIV
Enrollment	80 participants
Start Date	2026-10-29
Primary Completion	2027-12-02 (estimated)
Study Completion	2027-12-02 (estimated)
Updated on ClinicalTrials.gov	2026-09-30